PHARMAC is pleased to let you know about a recent decision to fund vildagliptin (Galvus) and vildagliptin with metformin (Galvumet) without funding restrictions for the treatment of type 2 diabetes mellitus. These products will be available fully funded from 1 October 2018.
Our decision for these products is part of multiproduct agreement involving 10 pharmaceuticals supplied by Novartis New Zealand Ltd. You can find out more about this decision and the consultation feedback received in the notification, which is available on the PHARMAC website and attached.
We’d like to thank everyone who responded to the consultation. The feedback we received was generally supportive of the proposal though some people raised concerns regarding PHARMAC’s assessment of these treatments and the desire to see other diabetes treatments funded. More information on the feedback PHARMAC received can be found on the PHARMAC website.
PHARMAC received expert advice from our advisory committees whose job is to review clinical data and help us understand the full benefits of these treatments. From there, PHARMAC undertook a full assessment of these treatments, including the impacts of funding these treatments on the health system.
The funding of vildagliptin and vildagliptin with metformin will not prevent the funding of other antidiabetic treatments at any time. PHARMAC is currently assessing a number of other medicines for the treatment of type 2 diabetes and we are hopeful that suppliers will work with us in relation to other diabetes treatments now that a new type of treatment is funded.
PHARMAC is working with bpacNZ to produce education material for health care professionals to help when prescribing the new treatments.
If you have any questions, please contact me. My contact details are as below.
Danae Staples-Moon | Senior Therapeutic Group Manager
PHARMAC | PO Box 10 254 | Level 9, 40 Mercer Street, Wellington
DDI: +64 4 916 7557 | F: +64 4 460 4995 | www.pharmac.health.nz